All Search Results
News Releases
Sep 28, 2026, 06:30 ET Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
data from the global Phase 3 BRUIN CLL-313 and BRUIN CLL-314 clinical trials. BRUIN CLL-313 is the first prospective, randomized Phase 3 study to examine the efficacy and safety of a non-covalent BTK inhibitor in patients with treatment-naïve CLL/SLL. In BRUIN CLL-313, the study demonstrated a statistically
More news about: Innovent Biologics
Sep 24, 2026, 07:24 ET ViferaXS wirbt 12 Millionen Euro ein, um Phase-II-Studie zur chronischen lymphatischen Leukämie voranzutreiben und seine onkologische Pipeline auszubauen
Beteiligung privater InvestorenMit den Erlösen werden eine Phase-II-Studie mit CLLTAXS01 bei chronischer lymphatischer Leukämie (CLL) sowie die bevorstehenden Auswertungen der Phase-I-Studien bei akuter myeloischer Leukämie (AML) und fibrolamellärem Karzinom (FLC) finanziert.
More news about: ViferaXS GmbH
Sep 23, 2026, 08:15 ET ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline
Huma, with participation from private investorsProceeds fund a Phase II trial of CLLTAXS01 in chronic lymphocytic leukemia (CLL), plus upcoming Phase I read-outs in acute myeloid leukemia (AML) and fibrolamellar carcinoma (FLC)TÜBINGEN,
More news about: ViferaXS GmbH
Sep 23, 2026, 02:15 ET ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline
Huma, with participation from private investorsProceeds fund a Phase II trial of CLLTAXS01 in chronic lymphocytic leukemia (CLL), plus upcoming Phase I read-outs in acute myeloid leukemia (AML) and fibrolamellar carcinoma (FLC)
More news about: ViferaXS GmbH
Sep 09, 2026, 10:31 ET Waldenström Macroglobulinemia Market to Gain Momentum During the Forecast Period (2026-2036) Due to Launch of Novel Drug Classes Including BTK Degraders, Non-covalent BTKi, BCL-2 Inhibitors, and Targeted Radiotherapeutics | DelveInsight
CNS-penetrating small-molecule degrader targeting Bruton's tyrosine kinase (BTK), currently under investigation for the treatment of chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and Waldenström macroglobulinemia (WM).The anticipated launch of these emerging therapies are poised to transform
More news about: DelveInsight Business Research, LLP
